Protagonist Therapeutics, Inc. announced the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024. Closing of the transaction was contingent on completion of review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the United States. Protagonist will receive the $300 million upfront payment associated with the transaction in the second quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.61 USD | +0.99% | +14.81% | +29.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.13% | 1.72B | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda